First Turn Management LLC Has $30.47 Million Stock Holdings in Vera Therapeutics, Inc. $VERA

First Turn Management LLC grew its position in Vera Therapeutics, Inc. (NASDAQ:VERA) by 69.7% during the 4th quarter, Holdings Channel reports. The firm owned 601,774 shares of the company’s stock after purchasing an additional 247,245 shares during the quarter. Vera Therapeutics makes up about 3.5% of First Turn Management LLC’s investment portfolio, making the stock its 13th biggest position. First Turn Management LLC’s holdings in Vera Therapeutics were worth $30,474,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in the business. GAMMA Investing LLC raised its holdings in shares of Vera Therapeutics by 50.5% in the fourth quarter. GAMMA Investing LLC now owns 703 shares of the company’s stock valued at $36,000 after buying an additional 236 shares during the last quarter. Optimize Financial Inc raised its holdings in shares of Vera Therapeutics by 1.5% in the fourth quarter. Optimize Financial Inc now owns 17,800 shares of the company’s stock valued at $901,000 after buying an additional 256 shares during the last quarter. Intech Investment Management LLC raised its holdings in shares of Vera Therapeutics by 2.4% in the fourth quarter. Intech Investment Management LLC now owns 17,838 shares of the company’s stock valued at $903,000 after buying an additional 424 shares during the last quarter. Invesco Ltd. raised its holdings in shares of Vera Therapeutics by 2.0% in the second quarter. Invesco Ltd. now owns 27,847 shares of the company’s stock valued at $656,000 after buying an additional 550 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Vera Therapeutics by 25.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,106 shares of the company’s stock valued at $157,000 after buying an additional 639 shares during the last quarter. 99.21% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. William Blair reaffirmed an “outperform” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. TD Cowen reaffirmed a “buy” rating on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Wolfe Research raised Vera Therapeutics from a “peer perform” rating to an “outperform” rating and set a $88.00 price target for the company in a report on Wednesday, March 11th. Evercore set a $91.00 price target on Vera Therapeutics in a report on Friday, May 15th. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and issued a $90.00 price target on shares of Vera Therapeutics in a report on Tuesday, June 2nd. Ten equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Vera Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $78.00.

Insiders Place Their Bets

In other Vera Therapeutics news, CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $36.74, for a total transaction of $679,690.00. Following the completion of the sale, the chief executive officer directly owned 216,744 shares of the company’s stock, valued at approximately $7,963,174.56. The trade was a 7.86% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

Vera Therapeutics Stock Performance

Shares of NASDAQ:VERA opened at $34.26 on Friday. The stock has a market capitalization of $2.46 billion, a P/E ratio of -6.18 and a beta of 0.93. Vera Therapeutics, Inc. has a 1-year low of $19.07 and a 1-year high of $56.05. The company has a current ratio of 13.64, a quick ratio of 13.64 and a debt-to-equity ratio of 0.15. The business has a 50-day moving average price of $37.02 and a two-hundred day moving average price of $41.38.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing the consensus estimate of ($1.33) by ($0.36). During the same period in the previous year, the company earned ($0.81) earnings per share. Equities analysts predict that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current year.

About Vera Therapeutics

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.